The companies will offer an integrated CDMO solution encompassing development, scale-up, regulatory support and commercial manufacturing of sterile APIs

| Photo Credit:

Mckyartstudio

Gland Pharma and Neuland Laboratories have entered into a long-term a contract development and manufacturing organisation (CDMO) partnership under which Gland will establish a sterile manufacturing suite for active pharmaceutical ingredients (APIs) pertaining to microparticle depot products. The collaboration combines Neuland’s complex API development and manufacturing capabilities including deep expertise in complex chemistry, process development, custom manufacturing with Gland Pharma’s global sterile manufacturing expertise to serve growing demand for sterile APIs used in microparticle depot products and other complex sterile APIs. The collaboration represents a significant expansion of the relationship between the two Hyderabad-based companies, creating a dedicated manufacturing platform that aligns their complementary capabilities under a long-term strategic partnership. Under the collaboration, Gland Pharma will expand its existing sterile manufacturing infrastructure through an additional dedicated suite at its JNPC facility at Visakhapatnam to support Neuland for its growing demand of sterile APIs. The facility will be constructed and operated to cGMP, USFDA and EU standards, and will be backed by Gland Pharma’s proven aseptic manufacturing expertise.Together, the companies will offer an integrated CDMO solution encompassing development, scale-up, regulatory support and commercial manufacturing of sterile APIs. The suite will be designed to add approximately 1,400 kg of annual capacity, providing manufacturing flexibility across multiple sterile products while supporting future growth. Srinivas Sadu, Executive Chairman, Gland Pharma said: “By leveraging the complementary strengths of both organisations, we will provide a robust and scalable CDMO solution backed by world-class quality, compliance and manufacturing excellence.” Saharsh Davuluri, CEO & MD, Neuland Laboratories said: “Together, we are strengthening our ability to deliver the quality, reliability, and supply assurance that innovators and generic companies expect from their CDMO partners.”Published on August 5, 2026